Elevated nocturnal NEFA are an early signal for hyperinsulinaemic compensation during diet-induced insulin resistance in dogs

Diabetologia

Volumn 58, Issue 11, 2015, Pages 2663-2670

  Broussard, Josiane L ^a   Kolka, Cathryn M ^a   Castro, Ana V B ^a   Asare Bediako, Isaac ^a   Paszkiewicz, Rebecca L ^a   Szczepaniak, Edward W ^a   Szczepaniak, Lidia S ^a   Knutson, Kristen L ^b   Kim, Stella P ^a   Bergman, Richard N ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Disposition index; Glucose tolerance; Insulin compensation; Non esterified fatty acids; Type 2 diabetes

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; FATTY ACID; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIET; DIET INDUCED INSULIN RESISTANCE; FAT INTAKE; FATTY ACID BLOOD LEVEL; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MONGREL DOG; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DOG; GLUCOSE BLOOD LEVEL; HYPERINSULINISM; PHYSIOLOGY; SECRETION (PROCESS); VETERINARY;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIET; DOGS; FATTY ACIDS, NONESTERIFIED; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE;

EID: 84942991544     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3721-6     Document Type: Article

References (47)

1. Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263–1268
2. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812
3. Kahn SE, Beard JC, Schwartz MW et al (1989) Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562–568
4. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794
5. Cerutti F, Sacchetti C, Bessone A, Rabbone I, Cavallo-Perin P, Pacini G (1998) Insulin secretion and hepatic insulin clearance as determinants of hyperinsulinaemia in normotolerant grossly obese adolescents. Acta Paediatr 87:1045–1050
6. Mittelman SD, van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49:2116–2125
7. Kim SP, Catalano KJ, Hsu IR, Chiu JD, Richey JM, Bergman RN (2007) Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia. Am J Physiol Endocrinol Metab 292:E1590–E1598
8. Schlierf G, Dorow E (1973) Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 52:732–740
9. Broussard JL, Chapotot F, Abraham V et al (2015) Sleep restriction increases free fatty acids in healthy men. Diabetologia 58:791–798
10. MacPherson RE, Castellani L, Beaudoin MS, Wright DC (2014) Evidence for fatty acids mediating CL 316,243-induced reductions in blood glucose in mice. Am J Physiol Endocrinol Metab 307:E563–E570
11. Lai E, Pettersson U, Verdugo AD et al (2014) Blood lipids affect rat islet blood flow regulation through beta(3)-adrenoceptors. Am J Physiol Endocrinol Metab 307:E653–E663
12. Staehr PM, Dhalla AK, Zack J et al (2013) Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol 53:385–392
13. Steil GM, Ader M, Moore DM, Rebrin K, Bergman RN (1996) Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest 97:1497–1503
14. Boden G (2005) Free fatty acids and insulin secretion in humans. Curr Diab Rep 5:167–170
15. Bergman RN (1989) Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38:1512–1527
16. Folsom AR, Jacobs DR Jr, Wagenknecht LE et al (1996) Increase in fasting insulin and glucose over seven years with increasing weight and inactivity of young adults. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 144:235–246
17. Tuunanen H, Engblom E, Naum A et al (2006) Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114:2130–2137
18. Lehto HR, Parkka J, Borra R et al (2012) Effects of acute and one-week fatty acid lowering on cardiac function and insulin sensitivity in relation with myocardial and muscle fat and adiponectin levels. J Clin Endocrinol Metab 97:3277–3284
19. Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L (2007) Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 321:327–333
20. Fatholahi M, Xiang Y, Wu Y et al (2006) A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 317:676–684
21. Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA (2004) Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 89:4649–4655
22. Bajaj M, Suraamornkul S, Romanelli A et al (2005) Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 54:3148–3153
23. Rigazio S, Lehto HR, Tuunanen H et al (2008) The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am J Physiol Endocrinol Metab 295:E413–E419
24. Daniele G, Eldor R, Merovci A et al (2014) Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes 63:2812–2820
25. Santomauro AT, Boden G, Silva ME et al (1999) Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836–1841
26. Liang H, Tantiwong P, Sriwijitkamol A et al (2013) Effect of a sustained reduction in plasma free fatty acid concentration on insulin signalling and inflammation in skeletal muscle from human subjects. J Physiol 591:2897–2909
27. Kelly JJ, Lawson JA, Campbell LV et al (2000) Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 14:567–572
28. Worm D, Henriksen JE, Vaag A, Thye-Ronn P, Melander A, Beck-Nielsen H (1994) Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717–721
29. Saloranta C, Taskinen MR, Widen E, Harkonen M, Melander A, Groop L (1993) Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 42:1559–1566
30. Vaag AA, Beck-Nielsen H (1992) Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol (Copenh) 127:344–350
31. Oh YT, Oh KS, Choi YM et al (2011) Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am J Physiol Endocrinol Metab 300:E1012–E1021
32. Leung N, Sakaue T, Carpentier A, Uffelman K, Giacca A, Lewis GF (2004) Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 47:204–213
33. Poynten AM, Gan SK, Kriketos AD et al (2003) Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metab Clin Exp 52:699–704
34. van de Weijer T, Phielix E, Bilet L et al (2015) Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes 64:1193–1201
35. Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM (2007) A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. Am J Physiol Endocrinol Metab 292:E1358–E1363
36. Shearer J, Severson DL, Su L, Belardinelli L, Dhalla AK (2009) Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther 328:306–311
37. DeFronzo RA (2004) Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl: 9–21
38. Boden G (2003) Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111:121–124
39. Boden G, Lebed B, Schatz M, Homko C, Lemieux S (2001) Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612–1617
40. Roden M, Price TB, Perseghin G et al (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859–2865
41. Chavez AO, Kamath S, Jani R et al (2010) Effect of short-term free fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals. J Clin Endocrinol Metab 95:422–429
42. Talukdar S, Olefsky JM, Osborn O (2011) Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32:543–550
43. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432–2437
44. Nagasumi K, Esaki R, Iwachidow K et al (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067–1076
45. Alquier T, Peyot ML, Latour MG et al (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58:2607–2615
46. Wagner R, Kaiser G, Gerst F et al (2013) Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 62:2106–2111
47. Burant CF, Viswanathan P, Marcinak J et al (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403–1411